Biotech growth moderates
Executive Summary
Global prescription sales of biotech drugs increased 12.5 percent in 2007 compared with 18.2 percent in 2006, according to IMS Health. Going forward, the research group predicts a more moderate growth environment through 2012 due to loss of exclusivity and competition from biosimilars, crowded therapy areas, payer reluctance to fund high-cost therapies and safety concerns. Sales gains in 2007 were led by oncologics and autoimmune agents, which each advanced by more than 24 percent. Overall biotech sales topped $75 million in 2007
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.